Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 438 articles:
HTML format



Single Articles


    June 2020
  1. ALBSHESH A, Ben-Horin S
    Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF?
    Aliment Pharmacol Ther. 2020;51:1198-1199.
    PubMed    


  2. SANDBORN WJ, Panes J, Sands BE, Reinisch W, et al
    Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1209-1210.
    PubMed    


  3. SANTA A, Szanto KJ, Sarlos P, Miheller P, et al
    Letter: suicide risk among adult inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020;51:1213-1214.
    PubMed    


  4. KOTZE PG, Teixeira FV, Damiao AOMC
    Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.
    Aliment Pharmacol Ther. 2020;51:1208-1209.
    PubMed    


  5. MALHAM M, Jakobsen C, Paerregaard A, Hald M, et al
    Letter: suicide risk among adult inflammatory bowel disease patients. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1214-1215.
    PubMed    


    May 2020
  6. SHAH A, Talley NJ, Koloski N, Macdonald GA, et al
    Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 15. doi: 10.1111/apt.15786.
    PubMed     Abstract available


  7. EVERHOV AH, Erichsen R, Sachs MC, Pedersen L, et al
    Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017.
    Aliment Pharmacol Ther. 2020 May 15. doi: 10.1111/apt.15785.
    PubMed     Abstract available


  8. WANG J, Prenner J, Wang W, Sakuraba A, et al
    Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15766.
    PubMed     Abstract available


  9. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15767.
    PubMed     Abstract available


  10. AXELRAD JE, Cadwell KH, Colombel JF, Shah SC, et al
    Systematic review: gastrointestinal infection and incident inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15770.
    PubMed     Abstract available


  11. BANGMA A, Voskuil MD, Uniken Venema WTC, Brugge H, et al
    Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15762.
    PubMed     Abstract available


    April 2020
  12. AL-ANI A, Prentice R, Rentsch C, Johnson D, et al
    Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.
    Aliment Pharmacol Ther. 2020 Apr 29. doi: 10.1111/apt.15779.
    PubMed     Abstract available


  13. KREIJNE JE, de Vries AC, de Veer RC, Bouma G, et al
    Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15734.
    PubMed     Abstract available


  14. SALAMEH R, Kirchgesner J, Allez M, Carbonnel F, et al
    Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15751.
    PubMed     Abstract available


  15. BIEMANS VBC, Savelkoul E, Gabriels RY, Simsek M, et al
    A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020 Apr 27. doi: 10.1111/apt.15730.
    PubMed     Abstract available


  16. DAUDE S, Remen T, Chateau T, Danese S, et al
    Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Apr 22. doi: 10.1111/apt.15739.
    PubMed     Abstract available


  17. LIU B, Wanders A, Wirdefeldt K, Sjolander A, et al
    Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register-based matched cohort study.
    Aliment Pharmacol Ther. 2020 Apr 22. doi: 10.1111/apt.15715.
    PubMed     Abstract available


  18. DULAI PS, Jairath V, Khanna R, Ma C, et al
    Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Apr 21. doi: 10.1111/apt.15726.
    PubMed     Abstract available


  19. KOCHHAR GS, Desai A, Syed A, Grover A, et al
    Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications.
    Aliment Pharmacol Ther. 2020 Apr 21. doi: 10.1111/apt.15721.
    PubMed     Abstract available


  20. AMIOT A, Filippi J, Abitbol V, Cadiot G, et al
    Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Aliment Pharmacol Ther. 2020 Apr 14. doi: 10.1111/apt.15717.
    PubMed     Abstract available


  21. LEE HH, Bae JM, Lee BI, Lee KM, et al
    Pregnancy outcomes in women with inflammatory bowel disease: A 10-year nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2020 Apr 7. doi: 10.1111/apt.15654.
    PubMed     Abstract available


  22. BIEMANS VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, et al
    Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15689.
    PubMed     Abstract available


  23. KING D, Reulen RC, Thomas T, Chandan JS, et al
    Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15701.
    PubMed     Abstract available


    March 2020
  24. LAURIOT DIT PREVOST C, Azahaf M, Nachury M, Branche J, et al
    Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lemann Index and Inflammatory Bowel Disease Disability Index.
    Aliment Pharmacol Ther. 2020 Mar 27. doi: 10.1111/apt.15681.
    PubMed     Abstract available


  25. HUPE M, Riviere P, Nancey S, Roblin X, et al
    Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Mar 22. doi: 10.1111/apt.15680.
    PubMed     Abstract available


  26. RODRIGUEZ-LAGO I, Castro-Poceiro J, Fernandez-Clotet A, Mesonero F, et al
    Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Mar 17. doi: 10.1111/apt.15687.
    PubMed     Abstract available


  27. PIOVANI D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, et al
    Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Mar 13. doi: 10.1111/apt.15692.
    PubMed     Abstract available


  28. MOURATIDOU N, Malmborg P, Sachs MC, Askling J, et al
    Adult height in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15667.
    PubMed     Abstract available


  29. BATTAT R
    Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis.
    Aliment Pharmacol Ther. 2020;51:663-664.
    PubMed    


  30. WEI B, Wang J, Zhang Y, Zhao J, et al
    Letter: inflammatory bowel disease and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2020;51:671-673.
    PubMed    


    February 2020
  31. D'AMICO F, Bonovas S, Danese S, Peyrin-Biroulet L, et al
    Review article: faecal calprotectin and histologic remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Feb 12. doi: 10.1111/apt.15662.
    PubMed     Abstract available


  32. PAI RK, Jairath V, Feagan BG
    Editorial: histologic normalisation in ulcerative colitis.
    Aliment Pharmacol Ther. 2020;51:399-401.
    PubMed    


  33. CUSHING KC, Ananthakrishnan AN
    Editorial: histologic normalisation in ulcerative colitis. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:401.
    PubMed    


  34. MOCCIARO F, Scimeca D, Conte E, Bonaccorso A, et al
    Letter: the gap between guidelines and real clinical practice for dysplasia surveillance in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;51:481-482.
    PubMed    


    January 2020
  35. SHAH ED, Coburn ES, Nayyar A, Lee KJ, et al
    Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15637.
    PubMed     Abstract available


  36. GIBSON DJ, Ward MG, Rentsch C, Friedman AB, et al
    Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Jan 21. doi: 10.1111/apt.15643.
    PubMed     Abstract available


  37. TANDON P, Govardhanam V, Leung K, Maxwell C, et al
    Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15587.
    PubMed     Abstract available


  38. KAYAL M, Ungaro R
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:190.
    PubMed    


  39. LAHARIE D, Riviere P
    Letter: should we intensify infliximab in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:186-187.
    PubMed    


  40. SEBASTIAN S
    Letter: should we intensify infliximab in acute severe ulcerative colitis? Author's reply.
    Aliment Pharmacol Ther. 2020;51:188.
    PubMed    


  41. YAMAMOTO T, Shimoyama T, Kotze PG
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:189-190.
    PubMed    


  42. PROBERT C
    Commentary: vitamin D supplementation in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:201-202.
    PubMed    


  43. TOWNSEND T, Subramanian S
    Editorial: endoscopic inflammation in ileoanal pouches-does it really matter?
    Aliment Pharmacol Ther. 2020;51:170-171.
    PubMed    


  44. BENSON-POPE SJ, Gearry RB
    Editorial: better outcomes for Crohn's disease-more than just the drugs?
    Aliment Pharmacol Ther. 2020;51:167-168.
    PubMed    


  45. HART A
    Commentary: safety of anti-TNF use in pregnancy.
    Aliment Pharmacol Ther. 2020;51:205-206.
    PubMed    


  46. KAYAL M, Ungaro R
    Editorial: endoscopic inflammation in ileoanal pouches-does it really matter? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:172.
    PubMed    


  47. LUBER RP, Irving PM
    Editorial: establishing a joint approach to a common problem for gastroenterologists.
    Aliment Pharmacol Ther. 2020;51:306-307.
    PubMed    


  48. WINTER RW
    Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study.
    Aliment Pharmacol Ther. 2020;51:307-308.
    PubMed    


    December 2019
  49. OLLECH JE, Dwadasi S, Rai V, Peleg N, et al
    Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 25. doi: 10.1111/apt.15616.
    PubMed     Abstract available


  50. DONG C, Metzger M, Holsbo E, Perduca V, et al
    Systematic review with meta-analysis: mortality in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 10. doi: 10.1111/apt.15592.
    PubMed     Abstract available


    November 2019
  51. DULAI PS, Singh S, Jairath V, Ma C, et al
    Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Nov 22. doi: 10.1111/apt.15577.
    PubMed     Abstract available


  52. CUSHING KC, Tan W, Alpers DH, Deshpande V, et al
    Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.
    Aliment Pharmacol Ther. 2019 Nov 7. doi: 10.1111/apt.15568.
    PubMed     Abstract available


  53. MOENS A, van der Woude CJ, Julsgaard M, Humblet E, et al
    Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
    Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15539.
    PubMed     Abstract available


  54. SOH H, Im JP, Han K, Park S, et al
    Crohn's disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study.
    Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15562.
    PubMed     Abstract available


  55. MENON S, Bressler B
    Editorial: aminosalicylates and nephrotoxicity-an issue put to rest.
    Aliment Pharmacol Ther. 2019;50:1059.
    PubMed    


    October 2019
  56. SANDS BE, Armuzzi A, Marshall JK, Lindsay JO, et al
    Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Aliment Pharmacol Ther. 2019 Oct 29. doi: 10.1111/apt.15555.
    PubMed     Abstract available


  57. PIOVANI D, Danese S, Peyrin-Biroulet L, Bonovas S, et al
    Inflammatory bowel disease: estimates from the global burden of disease 2017 study.
    Aliment Pharmacol Ther. 2019 Oct 29. doi: 10.1111/apt.15542.
    PubMed     Abstract available


  58. WILSON A, Peel C, Wang Q, Pananos AD, et al
    HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Oct 25. doi: 10.1111/apt.15563.
    PubMed     Abstract available


  59. VARKAS G, Ribbens C, Louis E, Van den Bosch F, et al
    Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies.
    Aliment Pharmacol Ther. 2019 Oct 25. doi: 10.1111/apt.15519.
    PubMed     Abstract available


  60. GUBATAN J, Chou ND, Nielsen OH, Moss AC, et al
    Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Oct 24. doi: 10.1111/apt.15506.
    PubMed     Abstract available


  61. LUU M, Benzenine E, Barkun A, Doret M, et al
    Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFalpha agents: a French nationwide population-based cohort.
    Aliment Pharmacol Ther. 2019 Oct 15. doi: 10.1111/apt.15504.
    PubMed     Abstract available


  62. SANDBORN WJ, Panes J, Sands BE, Reinisch W, et al
    Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
    Aliment Pharmacol Ther. 2019 Oct 9. doi: 10.1111/apt.15514.
    PubMed     Abstract available


  63. SELINGER CP, Parkes GC, Bassi A, Limdi JK, et al
    Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients.
    Aliment Pharmacol Ther. 2019 Oct 8. doi: 10.1111/apt.15497.
    PubMed     Abstract available


  64. LUND K, Larsen MD, Knudsen T, Kjeldsen J, et al
    The impact of anti-TNFalpha therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15510.
    PubMed     Abstract available


  65. DAI C, Jiang M, Sun MJ
    Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than IBD.
    Aliment Pharmacol Ther. 2019;50:834-835.
    PubMed    


  66. DOLINGER MT, Rolfes P, Phan BL, Dubinsky MC, et al
    Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;50:966-967.
    PubMed    


  67. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:970-971.
    PubMed    


  68. YAMAMOTO T, Kotze PG
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?
    Aliment Pharmacol Ther. 2019;50:969-970.
    PubMed    


  69. WALL CL, Day AS
    Editorial: the reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food reintroduction.
    Aliment Pharmacol Ther. 2019;50:824-825.
    PubMed    


  70. ASHTON JJ, Beattie RM
    Letter: anti-TNF therapy and intestinal resections in Crohn's disease-are we just delaying the inevitable?
    Aliment Pharmacol Ther. 2019;50:842-843.
    PubMed    


  71. KORZENIK J, Larsen MD, Nielsen J, Kjeldsen J, et al
    Editorial: anti-TNF therapy-a double-edged sword? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:823-824.
    PubMed    


  72. SCHREINER P, Biedermann L
    Editorial: anti-TNF therapy-a double-edged sword?
    Aliment Pharmacol Ther. 2019;50:822-823.
    PubMed    


    September 2019
  73. ASHTON JJ, Latham K, Beattie RM, Ennis S, et al
    Review article: the genetics of the human leucocyte antigen region in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Sep 13. doi: 10.1111/apt.15485.
    PubMed     Abstract available


  74. IANNONE A, Ruospo M, Palmer SC, Principi M, et al
    Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Sep 9. doi: 10.1111/apt.15493.
    PubMed     Abstract available


  75. MOORE G
    Editorial: UK quality of care drive improving ulcerative colitis hospital outcomes.
    Aliment Pharmacol Ther. 2019;50:601-602.
    PubMed    


  76. BODGER K
    Editorial: UK quality of care drive improving ulcerative colitis hospital outcomes. Author's reply.
    Aliment Pharmacol Ther. 2019;50:602-603.
    PubMed    


  77. MCCURDY JD
    Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease-author's reply.
    Aliment Pharmacol Ther. 2019;50:714-715.
    PubMed    


  78. ZENG J, Gan HT
    Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;50:712-713.
    PubMed    


  79. FRASCA JD, Cheifetz AS
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2019;50:599-600.
    PubMed    


  80. IBORRA M, Beltran B, Nos P
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:600-601.
    PubMed    


  81. DETLIE TE, Jahnsen J
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:610-611.
    PubMed    


  82. SEOW CH, Targownik LE
    Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes.
    Aliment Pharmacol Ther. 2019;50:603-604.
    PubMed    


  83. MUSGROVE J, Wolf M
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
    Aliment Pharmacol Ther. 2019;50:609-610.
    PubMed    


    August 2019
  84. CHOI YJ, Lee DH, Shin DW, Han KD, et al
    Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study.
    Aliment Pharmacol Ther. 2019 Aug 8. doi: 10.1111/apt.15446.
    PubMed     Abstract available


  85. BLACKWELL J, Saxena S, Alexakis C, Bottle A, et al
    The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study.
    Aliment Pharmacol Ther. 2019 Aug 6. doi: 10.1111/apt.15390.
    PubMed     Abstract available


  86. CARMODY JK, Plevinsky J, Peugh JL, Denson LA, et al
    Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Aug 2. doi: 10.1111/apt.15445.
    PubMed     Abstract available


  87. KREIJNE JE, de Veer RC, de Boer NK, Dijkstra G, et al
    Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
    Aliment Pharmacol Ther. 2019;50:407-415.
    PubMed     Abstract available


  88. LIN YS, Lin WC, Chen MJ, Wang YH, et al
    Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease-the jury might still be out. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:465-466.
    PubMed    


  89. GATES R, Fogel S, Nguyen VQ, Sorrentino D, et al
    Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease-the jury might still be out.
    Aliment Pharmacol Ther. 2019;50:464-465.
    PubMed    


  90. ISTL A, Yang ML, Fleshner KA, Parker CE, et al
    Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery.
    Aliment Pharmacol Ther. 2019;50:467-468.
    PubMed    


  91. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:469-470.
    PubMed    


  92. PAUL S, Roblin X
    Letter: immunogenicity of anti-TNF in elderly IBD patients.
    Aliment Pharmacol Ther. 2019;50:336.
    PubMed    


  93. SINGH S, Jairath V
    Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2019;50:337.
    PubMed    


  94. GARBO GM, Renna S, Caputo V, Orlando E, et al
    Letter: psoriasiform eruption during vedolizumab therapy.
    Aliment Pharmacol Ther. 2019;50:342-343.
    PubMed    


    July 2019
  95. SCHULTHEISS JPD, Brand EC, Lamers E, van den Berg WCM, et al
    Earlier discontinuation of TNF-alpha inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.
    Aliment Pharmacol Ther. 2019 Jul 16. doi: 10.1111/apt.15380.
    PubMed     Abstract available


  96. KORZENIK J, Larsen MD, Nielsen J, Kjeldsen J, et al
    Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Jul 2. doi: 10.1111/apt.15370.
    PubMed     Abstract available


  97. DETLIE TE, Lindstrom JC, Jahnsen ME, Finnes E, et al
    Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Aliment Pharmacol Ther. 2019 Jul 2. doi: 10.1111/apt.15386.
    PubMed     Abstract available


  98. BANERJEE T, Gearry R
    Editorial: suicide and IBD-a call to action.
    Aliment Pharmacol Ther. 2019;50:105-106.
    PubMed    


  99. BRYANT RV, Costello SP
    Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location.
    Aliment Pharmacol Ther. 2019;50:103-104.
    PubMed    


  100. MALHAM M, Jakobsen C, Hald M, Paerregaard A, et al
    Editorial: suicide and IBD-a call to action. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:106-107.
    PubMed    


  101. VANDE CASTEELE N, Jairath V
    Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:104-105.
    PubMed    


    June 2019
  102. TEPLER A, Narula N, Peek RM Jr, Patel A, et al
    Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Jun 5. doi: 10.1111/apt.15306.
    PubMed     Abstract available


  103. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Aliment Pharmacol Ther. 2019 Jun 5. doi: 10.1111/apt.15294.
    PubMed     Abstract available


  104. OLAISEN M, Fossmark R
    Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1532.
    PubMed    


  105. BUCHNER AM, Lichtenstein GR
    Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
    Aliment Pharmacol Ther. 2019;49:1531.
    PubMed    


  106. MURRAY CDR
    Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups?
    Aliment Pharmacol Ther. 2019;49:1528.
    PubMed    


  107. SINGH S, Jairath V, Lw S, G Z, et al
    Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1529.
    PubMed    


    May 2019
  108. SHAWIHDI M, Dodd S, Kallis C, Dixon P, et al
    Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005-2013.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15315.
    PubMed     Abstract available


  109. IANIRO G, Eusebi LH, Black CJ, Gasbarrini A, et al
    Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15330.
    PubMed     Abstract available


  110. MA C, Lee JK, Mitra AR, Teriaky A, et al
    Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 May 23. doi: 10.1111/apt.15297.
    PubMed     Abstract available


  111. MEYER A, Rudant J, Drouin J, Coste J, et al
    The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life.
    Aliment Pharmacol Ther. 2019 May 22. doi: 10.1111/apt.15323.
    PubMed     Abstract available


  112. MALHAM M, Jakobsen C, Paerregaard A, Virta LJ, et al
    The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study.
    Aliment Pharmacol Ther. 2019 May 8. doi: 10.1111/apt.15258.
    PubMed     Abstract available


  113. MCCURDY JD, Israel A, Hasan M, Weng R, et al
    A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 May 8. doi: 10.1111/apt.15286.
    PubMed     Abstract available


  114. MURPHY B, O'Kane D, McCourt C
    Letter: paradoxical skin eruptions during anti-TNF-alpha treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:1369-1370.
    PubMed    


    April 2019
  115. BOND A, Probert C
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1087-1088.
    PubMed    


  116. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1088-1089.
    PubMed    


  117. LEONG RWL, Kaakoush NO, Yau YY, Wasinger VC, et al
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?
    Aliment Pharmacol Ther. 2019;49:1086-1087.
    PubMed    


  118. CHAN SSM
    Editorial: differences in sex-based incidence of inflammatory bowel diseases between Asia-Pacific and Western countries - are these due to differences in environment, access to healthcare, or pathophysiology?
    Aliment Pharmacol Ther. 2019;49:1098-1099.
    PubMed    


  119. VERSTOCKT B, Vermeire S, Ferrante M, Breynaert C, et al
    Editorial: biomarker predictors of non-response to TNFalpha antagonists - the quest continues. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1091-1092.
    PubMed    


  120. SHOUVAL DS, Ben-Horin S
    Editorial: biomarker predictors of non-response to TNFalpha antagonists-the quest continues.
    Aliment Pharmacol Ther. 2019;49:1089-1090.
    PubMed    


  121. LIN YS, Cheng SW, Wang YH, Chen KH, et al
    Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:966-977.
    PubMed     Abstract available


  122. CASTIGLIONE F, Imperatore N, Testa A, De Palma GD, et al
    One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing.
    Aliment Pharmacol Ther. 2019;49:1026-1039.
    PubMed     Abstract available


  123. CATT H, Hughes D, Kirkham JJ, Bodger K, et al
    Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:978-996.
    PubMed     Abstract available


  124. ADAR T, Faleck D, Sasidharan S, Cushing K, et al
    Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Aliment Pharmacol Ther. 2019;49:873-879.
    PubMed     Abstract available


  125. SHAH SC, Khalili H, Chen CY, Ahn HS, et al
    Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.
    Aliment Pharmacol Ther. 2019;49:904-911.
    PubMed     Abstract available


    March 2019
  126. SIMSEK M, Lissenberg-Witte BI, van Riswijk MLM, Verschuren S, et al
    Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15229.
    PubMed     Abstract available


  127. OLAISEN M, Spigset O, Flatberg A, Granlund AVB, et al
    Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 20. doi: 10.1111/apt.15227.
    PubMed     Abstract available


  128. JACKSON B, Begun J, Gray K, Churilov L, et al
    Clinical decision support improves quality of care in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 7. doi: 10.1111/apt.15209.
    PubMed     Abstract available


  129. GIBSON DJ, Ward MG
    Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
    Aliment Pharmacol Ther. 2019;49:816-817.
    PubMed    


  130. BOUGUEN G, Siproudhis L
    Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:817-818.
    PubMed    


  131. VERSTOCKT B, Verstockt S, Creyns B, Tops S, et al
    Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:572-581.
    PubMed     Abstract available


    February 2019
  132. BANK S, Julsgaard M, Abed OK, Burisch J, et al
    Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 27. doi: 10.1111/apt.15187.
    PubMed     Abstract available


  133. DROBNE D, Kurent T, Golob S, Svegl P, et al
    Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 19. doi: 10.1111/apt.15179.
    PubMed     Abstract available


  134. SHIVAJI UN, Sharratt CL, Thomas T, Smith SCL, et al
    Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15097.
    PubMed     Abstract available


  135. SHAH A, Morrison M, Burger D, Martin N, et al
    Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15133.
    PubMed     Abstract available


  136. CHEN P, Li Y, Li L, Yu Q, et al
    Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 7. doi: 10.1111/apt.15159.
    PubMed     Abstract available


  137. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2019;49:477-478.
    PubMed    


  138. AHMED T, Brown F, Ahmed R, Shah A, et al
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;49:476-477.
    PubMed    


  139. DING R, Xu J, He Z, Chen Y, et al
    Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2019;49:345-346.
    PubMed    


  140. CHU TPC, Grainge MJ, Card TR
    Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2019;49:346.
    PubMed    


  141. PANES J, D'Haens GR, Higgins PDR, Mele L, et al
    Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
    Aliment Pharmacol Ther. 2019;49:265-276.
    PubMed     Abstract available


  142. LAI CY, Sung J, Cheng F, Tang W, et al
    Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2019;49:354-363.
    PubMed     Abstract available


    January 2019
  143. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
    Aliment Pharmacol Ther. 2019 Jan 31. doi: 10.1111/apt.15141.
    PubMed     Abstract available


  144. GHERSIN I, Khteeb N, Katz LH, Daher S, et al
    Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study.
    Aliment Pharmacol Ther. 2019 Jan 27. doi: 10.1111/apt.15160.
    PubMed     Abstract available


  145. OSTERMAN MT, Rosario M, Lasch K, Barocas M, et al
    Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15113.
    PubMed     Abstract available


  146. AGRAWAL M, Cohen-Mekelburg S, Kayal M, Axelrad J, et al
    Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15107.
    PubMed     Abstract available


  147. CHAPARRO M, Garre A, Ricart E, Iglesias-Flores E, et al
    Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU.
    Aliment Pharmacol Ther. 2019 Jan 13. doi: 10.1111/apt.15114.
    PubMed     Abstract available


  148. ASHTON JJ, Borca F, Mossotto E, Coelho T, et al
    Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood.
    Aliment Pharmacol Ther. 2019 Jan 9. doi: 10.1111/apt.15094.
    PubMed     Abstract available


  149. LUCIDARME C, Petitcollin A, Brochard C, Siproudhis L, et al
    Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Aliment Pharmacol Ther. 2019;49:147-154.
    PubMed     Abstract available


  150. MACALUSO FS, Cappello M, Giuffrida E, Fries W, et al
    Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
    Aliment Pharmacol Ther. 2019;49:234-236.
    PubMed    


  151. LEMBERG DA, Day AS
    Editorial: predicting response to treatment in children with Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:230-231.
    PubMed    


  152. HYAMS JS, Dubinsky M, Rosh J, Ruemmele FM, et al
    The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Aliment Pharmacol Ther. 2019;49:155-164.
    PubMed     Abstract available


  153. HALMOS EP, Mack A, Gibson PR
    Review article: emulsifiers in the food supply and implications for gastrointestinal disease.
    Aliment Pharmacol Ther. 2019;49:41-50.
    PubMed     Abstract available


    December 2018
  154. MA C, Guizzetti L, Cipriano LE, Parker CE, et al
    Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.
    Aliment Pharmacol Ther. 2018 Dec 19. doi: 10.1111/apt.15090.
    PubMed     Abstract available


  155. PARK SW, Kim TJ, Lee JY, Kim ER, et al
    Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study.
    Aliment Pharmacol Ther. 2018 Dec 2. doi: 10.1111/apt.15076.
    PubMed     Abstract available


  156. KAMM MA
    Editorial: treating strictures in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48.
    PubMed    


  157. RIEDER F, Feagan BG, Jairath V
    Editorial: treating strictures in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48.
    PubMed    


    November 2018
  158. SITTE J, Frentiu E, Baumann C, Rousseau H, et al
    Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.
    Aliment Pharmacol Ther. 2018 Nov 28. doi: 10.1111/apt.15057.
    PubMed     Abstract available


  159. NOURELDIN M, Higgins PDR, Govani SM, Cohen-Mekelburg S, et al
    Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.
    Aliment Pharmacol Ther. 2018 Nov 14. doi: 10.1111/apt.15023.
    PubMed     Abstract available


  160. PUREWAL S, Chapman S, Czuber-Dochan W, Selinger C, et al
    Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health.
    Aliment Pharmacol Ther. 2018 Nov 8. doi: 10.1111/apt.15019.
    PubMed     Abstract available


  161. ORFANOUDAKI E, Drygiannakis I, Koutroubakis IE
    Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Aliment Pharmacol Ther. 2018;48:1037-1038.
    PubMed    


  162. HANS AK, Scott FI
    Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection?
    Aliment Pharmacol Ther. 2018;48:1158-1159.
    PubMed    


  163. POTTER MD, Walker MM, Jones MP, Koloski NA, et al
    Letter: gluten sensitivity in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:1167-1168.
    PubMed    


  164. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:1159-1160.
    PubMed    


  165. AL SULAIS E, AlAmeel T
    Letter: faecal calprotectin, clinical indices and the diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:1166.
    PubMed    


    October 2018
  166. STEVENS TW, Matheeuwsen M, Lonnkvist MH, Parker CE, et al
    Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy.
    Aliment Pharmacol Ther. 2018 Oct 30. doi: 10.1111/apt.15033.
    PubMed     Abstract available


  167. PASCHOS P, Katsoula A, Salanti G, Giouleme O, et al
    Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Aliment Pharmacol Ther. 2018 Oct 30. doi: 10.1111/apt.15005.
    PubMed     Abstract available


  168. CHU TPC, Grainge MJ, Card TR
    The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity.
    Aliment Pharmacol Ther. 2018 Oct 8. doi: 10.1111/apt.15010.
    PubMed     Abstract available


  169. PHILPOTT H, Dougherty MK, Dellon ES
    Letter: screening for adrenal suppression in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2018;48:885-886.
    PubMed    


  170. CHAPARRO M, Garre A, Ricart E, Iborra M, et al
    Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2018;48:839-851.
    PubMed     Abstract available


  171. WOOD P, Henderson P
    Letter: screening for adrenal suppression in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:884-885.
    PubMed    


    September 2018
  172. CANETE F, Manosa M, Clos A, Cabre E, et al
    Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Sep 4. doi: 10.1111/apt.14956.
    PubMed     Abstract available


  173. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Editorial: anxiety and depression in inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2018;48:687-688.
    PubMed    


  174. LEE HH, Bae JM, Lee BI
    Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2018;48:684-685.
    PubMed    


  175. PARIENTE B, Blondeaux A
    Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:683-684.
    PubMed    


  176. MIKOCKA-WALUS A, Knowles SR
    Editorial: anxiety and depression in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:686-687.
    PubMed    


  177. WEINBERG EM, Reddy KR
    Editorial: leave it unhooked? Possible benefits of ileostomy over ileal-pouch-anal anastomosis in patients with ulcerative colitis and primary sclerosing cholangitis in the setting of liver transplantation.
    Aliment Pharmacol Ther. 2018;48:581-582.
    PubMed    


    August 2018
  178. DE FRANCISCO R, Castano-Garcia A, Martinez-Gonzalez S, Perez-Martinez I, et al
    Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Aug 10. doi: 10.1111/apt.14933.
    PubMed     Abstract available


  179. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the GETAID.
    Aliment Pharmacol Ther. 2018 Aug 2. doi: 10.1111/apt.14926.
    PubMed     Abstract available


  180. SAVOYE G, Fumery M, Gower-Rousseau C
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:384-385.
    PubMed    


  181. JULSGAARD M, Kjeldsen J, Brock B, Baumgart DC, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:386-388.
    PubMed    


  182. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:388-389.
    PubMed    


  183. MYRELID P
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery?
    Aliment Pharmacol Ther. 2018;48:383-384.
    PubMed    


  184. PEYRIN-BIROULET L, Lopez A, Cummings JRF, Dignass A, et al
    Review article: treating-to-target for inflammatory bowel disease-associated anaemia.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14922.
    PubMed     Abstract available


  185. ERIKSSON C, Henriksson I, Brus O, Zhulina Y, et al
    Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14920.
    PubMed     Abstract available


    July 2018
  186. KOTZE PG, Ma C, Almutairdi A, Al-Darmaki A, et al
    Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 31. doi: 10.1111/apt.14919.
    PubMed     Abstract available


  187. JOOSSE ME, Aardoom MA, Kemos P, Turner D, et al
    Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14893.
    PubMed     Abstract available


  188. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Systematic review with meta-analysis: anxiety and depression in children and adolescents with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14865.
    PubMed     Abstract available


  189. ANSARI AR, Aziz A
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:97-98.
    PubMed    


  190. FRIEDMAN AB, Sparrow MP
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:98-99.
    PubMed    


    June 2018
  191. HANLON I, Hewitt C, Bell K, Phillips A, et al
    Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 14. doi: 10.1111/apt.14840.
    PubMed     Abstract available


  192. VAN DEN BRINK G, Stapersma L, Vlug LE, Rizopolous D, et al
    Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 13. doi: 10.1111/apt.14832.
    PubMed     Abstract available


  193. PARK KT, Sceats L, Dehghan M, Trickey AW, et al
    Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 7. doi: 10.1111/apt.14842.
    PubMed     Abstract available


  194. GONCALVES J, Santos M, Acurcio R, Iria I, et al
    Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14808.
    PubMed     Abstract available


  195. BAE JM, Lee HH, Lee BI, Lee KM, et al
    Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14822.
    PubMed     Abstract available


  196. ALUKAIDEY S, Heerasing N
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice.
    Aliment Pharmacol Ther. 2018;47:1539-1540.
    PubMed    


  197. UNGARO R, Colombel JF
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1540.
    PubMed    


    May 2018
  198. TSE CS, Loftus EV Jr, Raffals LE, Gossard AA, et al
    Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 May 28. doi: 10.1111/apt.14829.
    PubMed     Abstract available


  199. SACLEUX SC, Sarter H, Fumery M, Charpentier C, et al
    Post-operative complications in elderly onset inflammatory bowel disease: a population-based study.
    Aliment Pharmacol Ther. 2018 May 8. doi: 10.1111/apt.14790.
    PubMed     Abstract available


  200. SEHGAL P, Colombel JF, Aboubakr A, Narula N, et al
    Systematic review: safety of mesalazine in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 May 3. doi: 10.1111/apt.14688.
    PubMed     Abstract available


  201. FRAGAKI M, Karmiris K
    Editorial: monitoring vedolizumab trough serum concentration in inflammatory bowel disease-following the fate of anti-TNF-alpha agents?
    Aliment Pharmacol Ther. 2018;47:1323-1324.
    PubMed    


  202. PAVLIDIS P, Graham J, Gulati S, Dubois P, et al
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1422-1423.
    PubMed    


  203. MANOSA M, Domenech E
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1421-1422.
    PubMed    


  204. CHRISTENSEN B, Gibson PR, Rubin DT
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1423-1424.
    PubMed    


  205. EVERHOV AH, Ludvigsson JF, Olen O
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1420-1421.
    PubMed    


  206. PAPAMICHAEL K, Cheifetz AS
    Letter: infliximab concentrations during induction therapy-one size does not fit all.
    Aliment Pharmacol Ther. 2018;47:1334-1335.
    PubMed    


  207. MAK WY, Ng SC
    Editorial: ways to reduce emergency department utilisation among IBD patients.
    Aliment Pharmacol Ther. 2018;47:1325-1326.
    PubMed    


    April 2018
  208. MA C, Guizzetti L, Panaccione R, Fedorak RN, et al
    Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 25. doi: 10.1111/apt.14672.
    PubMed     Abstract available


  209. WHITE JR, Phillips F, Monaghan T, Fateen W, et al
    Review article: novel oral-targeted therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Apr 19. doi: 10.1111/apt.14669.
    PubMed     Abstract available


  210. KURNOOL S, Nguyen NH, Proudfoot J, Dulai PS, et al
    High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14665.
    PubMed     Abstract available


  211. MONINUOLA OO, Milligan W, Lochhead P, Khalili H, et al
    Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
    Aliment Pharmacol Ther. 2018 Apr 5. doi: 10.1111/apt.14606.
    PubMed     Abstract available


  212. TALEBAN S
    Editorial: older-onset inflammatory bowel disease-is it time to start looking beyond a number?
    Aliment Pharmacol Ther. 2018;47:1034-1035.
    PubMed    


  213. MAGRO F, Sousa HT
    Editorial: ulcerative colitis submucosal fibrosis and inflammation: more than just strictures.
    Aliment Pharmacol Ther. 2018;47:1033-1034.
    PubMed    


  214. LIM MH, Doecke JD, Radford-Smith GL
    Editorial: first among Equals-not for either infliximab or adalimumab in Crohn's disease-yet.
    Aliment Pharmacol Ther. 2018;47:1225-1226.
    PubMed    


  215. TEICH N, Bruns T, Stallmach A
    Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype?
    Aliment Pharmacol Ther. 2018;47:1042-1043.
    PubMed    


  216. SPARROW MP
    Editorial: clinical trials in IBD-how much of a difference is enough?
    Aliment Pharmacol Ther. 2018;47:1032-1033.
    PubMed    


  217. MACALUSO FS, Orlando R, Renna S, Sapienza C, et al
    Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab.
    Aliment Pharmacol Ther. 2018;47:1040-1041.
    PubMed    


  218. STRIK AS, D'Haens GR
    Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1041-1042.
    PubMed    


  219. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1044-1045.
    PubMed    


    March 2018
  220. TANG MT, Keir ME, Erickson R, Stefanich EG, et al
    Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-beta7 integrin therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 30. doi: 10.1111/apt.14631.
    PubMed     Abstract available


  221. VOLLEBREGT PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, et al
    Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 9. doi: 10.1111/apt.14599.
    PubMed     Abstract available


  222. UNGARO R, Fausel R, Chang HL, Chang S, et al
    Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study.
    Aliment Pharmacol Ther. 2018 Mar 7. doi: 10.1111/apt.14569.
    PubMed     Abstract available


  223. WALKER GJ, Moore L, Heerasing N, Hendy P, et al
    Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
    Aliment Pharmacol Ther. 2018 Mar 5. doi: 10.1111/apt.14563.
    PubMed     Abstract available


  224. LAHARIE D, Riviere P
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:689-690.
    PubMed    


  225. QIU XY, Lu MJ, Zhang HJ
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:690-691.
    PubMed    


  226. LOBATON T, De Vos M
    Editorial: infliximab trough levels and histological healing in ulcerative colitis-a step towards personalised biologic therapy.
    Aliment Pharmacol Ther. 2018;47:855-856.
    PubMed    


  227. DE SIMONE C
    Letter: what gastroenterologists should know about VSL#3.
    Aliment Pharmacol Ther. 2018;47:698-699.
    PubMed    


  228. WILS P, Bouhnik Y, Michetti P, Flourie B, et al
    Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Aliment Pharmacol Ther. 2018;47:588-595.
    PubMed     Abstract available


  229. LIGHTNER AL, McKenna NP, Tse CS, Raffals LE, et al
    Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
    Aliment Pharmacol Ther. 2018;47:573-580.
    PubMed     Abstract available


  230. SINGH S, Andersen NN, Andersson M, Loftus EV Jr, et al
    Comparison of infliximab with adalimumab in 827 biologic-naive patients with Crohn's disease: a population-based Danish cohort study.
    Aliment Pharmacol Ther. 2018;47:596-604.
    PubMed     Abstract available


  231. VAN BODEGRAVEN AA, Boone NW
    Editorial: nocebo effect and switching to biosimilars.
    Aliment Pharmacol Ther. 2018;47:850-851.
    PubMed    


  232. PRATAP MOULI V, Kedia S, Ahuja V
    Letter: mucosal response in discriminating intestinal tuberculosis from Crohn's disease-when to look for it? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:860-861.
    PubMed    


  233. SHARMA V, Mandavdhare HS, Dutta U
    Letter: mucosal response in discriminating intestinal tuberculosis from Crohn's disease-when to look for it?
    Aliment Pharmacol Ther. 2018;47:859-860.
    PubMed    


  234. BEN-HORIN S
    Editorial: restoring therapeutic infliximab drug levels in patients with loss of response-pharmacokinetics and anti-drug antibodies as useful guidance tools.
    Aliment Pharmacol Ther. 2018;47:845-846.
    PubMed    


    February 2018
  235. BARRE A, Colombel JF, Ungaro R
    Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Feb 12. doi: 10.1111/apt.14550.
    PubMed     Abstract available


  236. BALLOU S, Hirsch W, Singh P, Rangan V, et al
    Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014.
    Aliment Pharmacol Ther. 2018 Feb 7. doi: 10.1111/apt.14551.
    PubMed     Abstract available


  237. GORDON IO, Agrawal N, Willis E, Goldblum JR, et al
    Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation.
    Aliment Pharmacol Ther. 2018 Feb 6. doi: 10.1111/apt.14526.
    PubMed     Abstract available


  238. RIBALDONE DG, Saracco GM, Astegiano M, Pellicano R, et al
    Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
    Aliment Pharmacol Ther. 2018;47:448-449.
    PubMed    


  239. COTE-DAIGNEAULT J, Luong ML, Colombel JF, Peerani F, et al
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2018;47:446-447.
    PubMed    


  240. KHAN N, Lewis JD
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications-authors' reply.
    Aliment Pharmacol Ther. 2018;47:448.
    PubMed    


  241. PAPAMICHAEL K, Cheifetz AS
    Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:436-437.
    PubMed    


  242. TSAI HH
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
    Aliment Pharmacol Ther. 2018;47:539-540.
    PubMed    


  243. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:540-541.
    PubMed    


  244. BARCLAY ML, Stamp LK
    Editorial: vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:535-536.
    PubMed    


  245. PRIMAS C, Reinisch S, Novacek G
    Letter: addition of azathioprine to infliximab maintenance therapy in patients with anti-drug antibodies and subclinical inflammation.
    Aliment Pharmacol Ther. 2018;47:544-545.
    PubMed    


  246. TAO P, Wang SY
    Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated.
    Aliment Pharmacol Ther. 2018;47:443.
    PubMed    


  247. SABINO J, Torres J
    Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2018;47:439-440.
    PubMed    


  248. JALANKA J, Hillamaa A, Satokari R, Mattila E, et al
    The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection.
    Aliment Pharmacol Ther. 2018;47:371-379.
    PubMed     Abstract available


  249. DREESEN E, Van Stappen T, Ballet V, Peeters M, et al
    Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Aliment Pharmacol Ther. 2018;47:346-355.
    PubMed     Abstract available


    January 2018
  250. YACOUB W, Williet N, Pouillon L, Di-Bernado T, et al
    Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Aliment Pharmacol Ther. 2018 Jan 31. doi: 10.1111/apt.14548.
    PubMed     Abstract available


  251. CHRISTENSEN B, Micic D, Gibson PR, Yarur A, et al
    Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14525.
    PubMed     Abstract available


  252. MANOSA M, Calafat M, de Francisco R, Garcia C, et al
    Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.
    Aliment Pharmacol Ther. 2018 Jan 25. doi: 10.1111/apt.14494.
    PubMed     Abstract available


  253. WALJEE AK, Liu B, Sauder K, Zhu J, et al
    Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14510.
    PubMed     Abstract available


  254. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Meade L, et al
    Systematic review: psychosocial factors associated with pain in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14493.
    PubMed     Abstract available


  255. OLIVERA P, Sandborn WJ, Panes J, Baumann C, et al
    Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
    Aliment Pharmacol Ther. 2018 Jan 19. doi: 10.1111/apt.14514.
    PubMed     Abstract available


  256. COLIZZO FP, Friedman LS
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:143-144.
    PubMed    


  257. BROEKMAN MMTJ, Wanten GJ, de Jong DJ
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:130-131.
    PubMed    


  258. SELINGER CP, Parkes GC, Raine T
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease-Author's reply.
    Aliment Pharmacol Ther. 2018;47:145.
    PubMed    


  259. WILLINGTON AJ, Gearry RB
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing.
    Aliment Pharmacol Ther. 2018;47:129-130.
    PubMed    


  260. MURRAY CD
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine.
    Aliment Pharmacol Ther. 2018;47:141-142.
    PubMed    


  261. MEIJER B, de Boer NKH
    Letter: thiopurines - is less really more?
    Aliment Pharmacol Ther. 2018;47:149.
    PubMed    


  262. DING NS, Malietzis G, Hart AL
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:142-143.
    PubMed    


  263. EBERHARDSON M, Soderling JK, Olen O
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:147-148.
    PubMed    


  264. RIBALDONE DG, Saracco G, Astegiano M, Pellicano R, et al
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?
    Aliment Pharmacol Ther. 2018;47:146-147.
    PubMed    


  265. LANG BM, Biedermann L, van Haaften WT, de Valliere C, et al
    Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:55-66.
    PubMed     Abstract available


  266. VANDE CASTEELE N, Feagan BG, Vermeire S, Yassine M, et al
    Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:229-237.
    PubMed     Abstract available


  267. BAR-YOSEPH H, Levhar N, Selinger L, Manor U, et al
    Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Aliment Pharmacol Ther. 2018;47:212-218.
    PubMed     Abstract available


  268. NORDENVALL C, Olen O, Nilsson PJ, von Seth E, et al
    Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.
    Aliment Pharmacol Ther. 2018;47:238-245.
    PubMed     Abstract available


  269. ADAMS A, Kalla R, Satsangi J
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD.
    Aliment Pharmacol Ther. 2018;47:306-307.
    PubMed    


  270. SAWBRIDGE D, Subramanian S
    Editorial: the IBD-disability index-ready for prime time?
    Aliment Pharmacol Ther. 2018;47:298-299.
    PubMed    


  271. LANG BM, Beerenwinkel N, Misselwitz B
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:307-308.
    PubMed    


    December 2017
  272. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14483.
    PubMed     Abstract available


  273. TADBIRI S, Peyrin-Biroulet L, Serrero M, Filippi J, et al
    Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Aliment Pharmacol Ther. 2017 Dec 18. doi: 10.1111/apt.14419.
    PubMed     Abstract available


  274. PAPAMICHAEL K, Rakowsky S, Rivera C, Cheifetz AS, et al
    Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 6. doi: 10.1111/apt.14458.
    PubMed     Abstract available


  275. SCHMITZ EMH, Boekema PJ, Straathof JWA, van Renswouw DC, et al
    Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14453.
    PubMed     Abstract available


  276. LU MJ, Qiu XY, Mao XQ, Li XT, et al
    Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14436.
    PubMed     Abstract available


  277. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14449.
    PubMed     Abstract available


  278. SINGH S, Fumery M, Sandborn WJ, Murad MH, et al
    Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14422.
    PubMed     Abstract available


  279. LOGAN M, Ijaz UZ, Hansen R, Gerasimidis K, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Aliment Pharmacol Ther. 2017;46.
    PubMed    


  280. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46.
    PubMed    


  281. DOMENECH E, Canete F, Manosa M
    Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?
    Aliment Pharmacol Ther. 2017;46.
    PubMed    


  282. MARTINEAU C, Flourie B, Wils P, Vaysse T, et al
    Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Abstract available


  283. MITREV N, Vande Casteele N, Seow CH, Andrews JM, et al
    Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Abstract available


    November 2017
  284. YU H, MacIsaac D, Wong JJ, Sellers ZM, et al
    Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2017 Nov 22. doi: 10.1111/apt.14430.
    PubMed     Abstract available


  285. COLOMBEL JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, et al
    Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Nov 21. doi: 10.1111/apt.14420.
    PubMed     Abstract available


  286. AYUBI E, Safiri S
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017;46:901-902.
    PubMed    


  287. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:902-903.
    PubMed    


  288. GOUYNOU C, Peyrin-Biroulet L
    Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
    Aliment Pharmacol Ther. 2017;46:1019-1020.
    PubMed    


  289. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46:1026-1027.
    PubMed    


  290. DAI C, Cao Q, Jiang M
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:1025-1026.
    PubMed    


  291. FIORINO G, Correale C, Radice S, Allocca M, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Aliment Pharmacol Ther. 2017;46:903-905.
    PubMed    


  292. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:897-898.
    PubMed    


  293. KOMAKI Y, Yamada A, Komaki F, Sakuraba A, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2017;46:905-906.
    PubMed    


  294. H ALLIN K, Jess T
    Editorial: do thiopurines and biologics decrease the risk of colectomy?
    Aliment Pharmacol Ther. 2017;46:896-897.
    PubMed    


  295. NAKASE H, Motoya S, Matsumoto T, Watanabe K, et al
    Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Aliment Pharmacol Ther. 2017;46:873-882.
    PubMed     Abstract available


  296. DING NS, Malietzis G, Lung PFC, Penez L, et al
    The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm.
    Aliment Pharmacol Ther. 2017;46:883-891.
    PubMed     Abstract available


  297. CARDING SR, Davis N, Hoyles L
    Review article: the human intestinal virome in health and disease.
    Aliment Pharmacol Ther. 2017;46:800-815.
    PubMed     Abstract available


    October 2017
  298. KUMP P, Wurm P, Grochenig HP, Wenzl H, et al
    The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Oct 20. doi: 10.1111/apt.14387.
    PubMed     Abstract available


  299. MCILROY J, Ianiro G, Mukhopadhya I, Hansen R, et al
    Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
    Aliment Pharmacol Ther. 2017 Oct 16. doi: 10.1111/apt.14384.
    PubMed     Abstract available


  300. LO B, Prosberg MV, Gluud LL, Chan W, et al
    Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.
    Aliment Pharmacol Ther. 2017 Oct 9. doi: 10.1111/apt.14373.
    PubMed     Abstract available


  301. SWAMINATH A, Feathers A, Ananthakrishnan AN, Falzon L, et al
    Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:645-656.
    PubMed     Abstract available


  302. ACTIS GC, Pellicano R
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset.
    Aliment Pharmacol Ther. 2017;46:768.
    PubMed    


  303. DAMAS O, Abreu MT
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:768-769.
    PubMed    


  304. LUNG PFC, Ng SC
    Editorial: challenges in the development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:696.
    PubMed    


    September 2017
  305. BERNSTEIN CN
    Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14338.
    PubMed     Abstract available


  306. SELINGER CP, Parkes GC, Bassi A, Fogden E, et al
    A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14334.
    PubMed     Abstract available


  307. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
    Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
    Aliment Pharmacol Ther. 2017 Sep 15. doi: 10.1111/apt.14323.
    PubMed     Abstract available


  308. XU L, Lochhead P, Ko Y, Claggett B, et al
    Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Sep 11. doi: 10.1111/apt.14291.
    PubMed     Abstract available


  309. ALEXAKIS C, Kumar S, Saxena S, Hotopf M, et al
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply.
    Aliment Pharmacol Ther. 2017;46:554-555.
    PubMed    


  310. KEEFER L
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care.
    Aliment Pharmacol Ther. 2017;46:553-554.
    PubMed    


  311. GRACIE DJ, Derwa Y, Hamlin PJ, Ford AC, et al
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:633-634.
    PubMed    


  312. SHANAHAN F
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts?
    Aliment Pharmacol Ther. 2017;46:632-633.
    PubMed    


  313. LIM MH, Radford-Smith GL
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet?
    Aliment Pharmacol Ther. 2017;46:630-631.
    PubMed    


  314. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:631-632.
    PubMed    


  315. EBERHARDSON M, Soderling JK, Neovius M, Cars T, et al
    Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.
    Aliment Pharmacol Ther. 2017;46:589-598.
    PubMed     Abstract available


  316. SAMAAN MA, Puylaert CAJ, Levesque BG, Zou GY, et al
    The development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:516-528.
    PubMed     Abstract available


  317. SPEIGHT RA, Mansfield JC
    Editorial: how effective is vedolizumab in the 'real world'?
    Aliment Pharmacol Ther. 2017;46:555-556.
    PubMed    


    August 2017
  318. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010.
    Aliment Pharmacol Ther. 2017 Aug 17. doi: 10.1111/apt.14268.
    PubMed     Abstract available


  319. KHAN N, Shah Y, Trivedi C, Lewis JD, et al
    Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2017 Aug 14. doi: 10.1111/apt.14257.
    PubMed     Abstract available


  320. DAMAS OM, Schwartz SJ, Abreu MT
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2017;46:467.
    PubMed    


  321. KUENZIG ME, Benchimol EI
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;46:465-466.
    PubMed    


  322. WISKIN AE, Sandhu BK
    Editorial: changing nature of paediatric IBD-new insights from Irish data.
    Aliment Pharmacol Ther. 2017;46:457-458.
    PubMed    


  323. SEOW CH, Panaccione R
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?
    Aliment Pharmacol Ther. 2017;46:463-464.
    PubMed    


  324. HUSSEY S
    Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply.
    Aliment Pharmacol Ther. 2017;46:458-459.
    PubMed    


  325. WARD MG, Irving PM
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:465.
    PubMed    


  326. WILLIAMS HRT, Orchard TR
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential.
    Aliment Pharmacol Ther. 2017;46:371-372.
    PubMed    


  327. SMOLINSKA A, van Schooten FJ
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:372.
    PubMed    


    July 2017
  328. COATES MD, Tekin I, Vrana KE, Mawe GM, et al
    Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jul 24. doi: 10.1111/apt.14226.
    PubMed     Abstract available


  329. UNGARO RC, Colombel JF
    Editorial: biologics in inflammatory bowel disease-time for direct comparisons.
    Aliment Pharmacol Ther. 2017;46:68-69.
    PubMed    


  330. ANDREWS JM
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities?
    Aliment Pharmacol Ther. 2017;46:201-202.
    PubMed    


  331. CRAMER H, Dobos G, Langhorst J
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:202-203.
    PubMed    


  332. VAN HAAFTEN WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, et al
    Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:26-39.
    PubMed     Abstract available


  333. WARD MG, Warner B, Unsworth N, Chuah SW, et al
    Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Aliment Pharmacol Ther. 2017;46:150-161.
    PubMed     Abstract available


  334. ANANTHAKRISHNAN AN, Sakuraba A, Barnes EL, Pekow J, et al
    The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:162-168.
    PubMed     Abstract available


  335. IMPERATORE N, Testa A, Caporaso N, Rispo A, et al
    Letter: anti-TNF dose de-escalation in Crohn's disease-a case-by-case decision.
    Aliment Pharmacol Ther. 2017;46:212.
    PubMed    


  336. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Editorial: which iron preparation for patients with IBD? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:195-196.
    PubMed    


  337. KENNEDY NA, Goodhand JR, Rampton DS
    Editorial: which iron preparation for patients with IBD?
    Aliment Pharmacol Ther. 2017;46:194-195.
    PubMed    


  338. PORTER CK, Riddle MS, Hooper TI
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st Century. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:64-65.
    PubMed    


  339. KAPLAN GG
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st century.
    Aliment Pharmacol Ther. 2017;46:63-64.
    PubMed    


  340. WANG S, Lin J
    Letter: determining the dominant role of environmental factors in UC development.
    Aliment Pharmacol Ther. 2017;46:77-78.
    PubMed    


    June 2017
  341. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017 Jun 30. doi: 10.1111/apt.14205.
    PubMed     Abstract available


  342. DERWA Y, Gracie DJ, Hamlin PJ, Ford AC, et al
    Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 27. doi: 10.1111/apt.14203.
    PubMed     Abstract available


  343. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 14. doi: 10.1111/apt.14173.
    PubMed     Abstract available


  344. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2017 Jun 8. doi: 10.1111/apt.14167.
    PubMed     Abstract available


  345. ALEXAKIS C, Kumar S, Saxena S, Pollok R, et al
    Systematic review and meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 2. doi: 10.1111/apt.14171.
    PubMed     Abstract available


  346. D'HAENS GR, Sandborn WJ, Zou G, Stitt LW, et al
    Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 1. doi: 10.1111/apt.14164.
    PubMed     Abstract available


  347. STIDHAM RW, Waljee AK
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1551-1552.
    PubMed    


  348. COLLINS PD
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.
    Aliment Pharmacol Ther. 2017;45:1553-1554.
    PubMed    


  349. HOLT DQ, Moore GT, Strauss BJG, Hamilton AL, et al
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1552-1553.
    PubMed    


  350. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply.
    Aliment Pharmacol Ther. 2017;45:1554-1555.
    PubMed    


  351. VANDE CASTEELE N, Gils A
    Editorial: variability in adalimumab trough and peak serum concentrations.
    Aliment Pharmacol Ther. 2017;45:1475-1476.
    PubMed    


  352. JAIRATH V, Feagan BG
    Editorial: the impact of the placebo effect in Crohn's disease - author's reply.
    Aliment Pharmacol Ther. 2017;45:1472.
    PubMed    


  353. BERNSTEIN CN
    Editorial: the impact of the placebo effect in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1471-1472.
    PubMed    


  354. WARD MG, Gibson PR, Sparrow MP
    Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1476-1477.
    PubMed    


    May 2017
  355. DAMAS OM, Avalos DJ, Palacio AM, Gomez L, et al
    Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.
    Aliment Pharmacol Ther. 2017 May 19. doi: 10.1111/apt.14145.
    PubMed     Abstract available


  356. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 May 4. doi: 10.1111/apt.14108.
    PubMed     Abstract available


  357. CHRISTENSEN B, Sparrow MP
    Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?
    Aliment Pharmacol Ther. 2017;45:1274-1275.
    PubMed    


  358. LAMBA MJ, Tharayil VS, Gearry RB
    Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?
    Aliment Pharmacol Ther. 2017;45:1367-1368.
    PubMed    


  359. NELSON A, Tsai HH
    Editorial: Clostridium difficile and inflammatory bowel disease - is it always a bad combination?
    Aliment Pharmacol Ther. 2017;45:1368-1369.
    PubMed    


  360. EVERHOV AH, Olen O, Ludvigsson JF
    Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children.
    Aliment Pharmacol Ther. 2017;45:1369-1370.
    PubMed    


  361. HAWTHORNE AB
    Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;45:1365-1366.
    PubMed    


  362. MA C, Fedorak RN, Kaplan GG, Dieleman LA, et al
    Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Aliment Pharmacol Ther. 2017;45:1232-1243.
    PubMed     Abstract available


  363. HOLT DQ, Moore GT, Strauss BJ, Hamilton AL, et al
    Visceral adiposity predicts post-operative Crohn's disease recurrence.
    Aliment Pharmacol Ther. 2017;45:1255-1264.
    PubMed     Abstract available


  364. KHORRAMI S, Gisbert JP
    Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.
    Aliment Pharmacol Ther. 2017;45:1374-1375.
    PubMed    


  365. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1372.
    PubMed    


  366. FELWICK R, Cummings JRF
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1370-1371.
    PubMed    


  367. SHIM HH, Seow CH
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
    Aliment Pharmacol Ther. 2017;45:1283-1284.
    PubMed    


  368. MITREV N, Kariyawasam V, Leong RW
    Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
    Aliment Pharmacol Ther. 2017;45:1279-1280.
    PubMed    


  369. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1284.
    PubMed    


    April 2017
  370. RODA G, Narula N, Pinotti R, Skamnelos A, et al
    Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14063.
    PubMed     Abstract available


  371. BYE WA, Jairath V, Travis SPL
    Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14075.
    PubMed     Abstract available


  372. ROBLIN X, Boschetti G, Williet N, Nancey S, et al
    Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14106.
    PubMed     Abstract available


  373. COUGHLAN A, Wylde R, Lafferty L, Quinn S, et al
    A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14070.
    PubMed     Abstract available


  374. CRAMER H, Schafer M, Schols M, Kocke J, et al
    Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 5. doi: 10.1111/apt.14062.
    PubMed     Abstract available


  375. JAIRATH V, Casteele NV, Hindryckx P
    Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1170-1171.
    PubMed    


  376. CHOY MC, De Cruz P
    Letter: dose optimising infliximab in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017;45:1169-1170.
    PubMed    


  377. ANGELISON L, Marsal J, Hertervig E
    Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1177-1178.
    PubMed    


  378. KILINCALP S, Ustun Y, Simsek Z
    Letter: how to define remission in ulcerative colitis - histological remission should be considered.
    Aliment Pharmacol Ther. 2017;45:1177.
    PubMed    


  379. YARUR AJ, Kanagala V, Stein DJ, Czul F, et al
    Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:933-940.
    PubMed     Abstract available


  380. VAN STEENBERGEN S, Bian S, Vermeire S, Van Assche G, et al
    Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Aliment Pharmacol Ther. 2017;45:923-932.
    PubMed     Abstract available


  381. ALLEN PB, Olivera P, Emery P, Moulin D, et al
    Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
    Aliment Pharmacol Ther. 2017;45:1058-1072.
    PubMed     Abstract available


  382. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1043-1057.
    PubMed     Abstract available


  383. WARD MG, Thwaites PA, Beswick L, Hogg J, et al
    Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1135-1145.
    PubMed     Abstract available


  384. HAMMER T, Lophaven SN, Nielsen KR, von Euler-Chelpin M, et al
    Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.
    Aliment Pharmacol Ther. 2017;45:1107-1114.
    PubMed     Abstract available


  385. JAIRATH V, Zou G, Parker CE, MacDonald JK, et al
    Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1021-1042.
    PubMed     Abstract available


  386. ANANTHAKRISHNAN AN
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Aliment Pharmacol Ther. 2017;45:1168.
    PubMed    


  387. VEGH Z, Bessissow T, Afif W, Lakatos PL, et al
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator?
    Aliment Pharmacol Ther. 2017;45:1167.
    PubMed    


    March 2017
  388. CHOLAPRANEE A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14030.
    PubMed     Abstract available


  389. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14043.
    PubMed     Abstract available


  390. SEOW CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, et al
    The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14040.
    PubMed     Abstract available


  391. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 6. doi: 10.1111/apt.14023.
    PubMed     Abstract available


  392. ARTOM M, Czuber-Dochan W, Norton C
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply.
    Aliment Pharmacol Ther. 2017;45:763-764.
    PubMed    


  393. GRACIE DJ, Ford AC
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain.
    Aliment Pharmacol Ther. 2017;45:762-763.
    PubMed    


  394. HEERASING N, Thompson B, Hendy P, Heap GA, et al
    Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:660-669.
    PubMed     Abstract available


  395. WINTER RW, Collins E, Cao B, Carrellas M, et al
    Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:653-659.
    PubMed     Abstract available


  396. SEGAL JP, Ding NS, Worley G, Mclaughlin S, et al
    Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm.
    Aliment Pharmacol Ther. 2017;45:581-592.
    PubMed     Abstract available


  397. RADFORD-SMITH GL, Hartnell F, Doecke JD
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Aliment Pharmacol Ther. 2017;45:856-857.
    PubMed    


  398. YAMAMOTO T, Shimoyama T
    Letter: small bowel recurrence and fate of the rectum after total colectomy and ileostomy for Crohn's colitis.
    Aliment Pharmacol Ther. 2017;45:863.
    PubMed    


  399. FRASER AG
    Editorial: can we get more clinical benefit from thiopurine metabolite testing?
    Aliment Pharmacol Ther. 2017;45:857-858.
    PubMed    


  400. BARREIRO-DE ACOSTA M, Gisbert JP
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
    Aliment Pharmacol Ther. 2017;45:855-856.
    PubMed    


  401. WONG DR, Hooymans PM
    Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:858-859.
    PubMed    


  402. BEN-HORIN S, Ungar B, Roblin X
    Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:760-762.
    PubMed    


    February 2017
  403. SMOLINSKA A, Bodelier AG, Dallinga JW, Masclee AA, et al
    The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Feb 26. doi: 10.1111/apt.14004.
    PubMed     Abstract available


  404. STRIK AS, van den Brink GR, Ponsioen C, Mathot R, et al
    Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13994.
    PubMed     Abstract available


  405. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Abstract available


  406. LOPHAVEN SN, Lynge E, Burisch J
    The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13971.
    PubMed     Abstract available


  407. LAW CC, Tariq R, Khanna S, Murthy S, et al
    Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 16. doi: 10.1111/apt.13972.
    PubMed     Abstract available


  408. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 7. doi: 10.1111/apt.13960.
    PubMed     Abstract available


  409. DOECKE JD, Hartnell F, Bampton P, Bell S, et al
    Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
    Aliment Pharmacol Ther. 2017;45:542-552.
    PubMed     Abstract available


  410. FUMERY M, Dulai PS, Meirick P, Farrell AM, et al
    Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.
    Aliment Pharmacol Ther. 2017;45:381-390.
    PubMed     Abstract available


    January 2017
  411. DIEDEREN K, Hoekman DR, Leek A, Wolters VM, et al
    Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Aliment Pharmacol Ther. 2017 Jan 31. doi: 10.1111/apt.13950.
    PubMed     Abstract available


  412. VUITTON L, Peyrin-Biroulet L, Colombel JF, Pariente B, et al
    Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
    Aliment Pharmacol Ther. 2017 Jan 23. doi: 10.1111/apt.13948.
    PubMed     Abstract available


  413. HINDRYCKX P, Novak G, Vande Casteele N, Laukens D, et al
    Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jan 11. doi: 10.1111/apt.13913.
    PubMed     Abstract available


  414. HARTERY K, O'Reilly S, Houlihan D, Doherty G, et al
    Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2017;45:376-378.
    PubMed    


  415. HONG SN, Kim HJ, Kim KH, Han SJ, et al
    Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Aliment Pharmacol Ther. 2017;45:253-263.
    PubMed     Abstract available


  416. GREGOIRE C, Lechanteur C, Briquet A, Baudoux E, et al
    Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:205-221.
    PubMed     Abstract available


  417. UNGAR B, Kopylov U, Engel T, Yavzori M, et al
    Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
    Aliment Pharmacol Ther. 2017;45:276-282.
    PubMed     Abstract available


  418. PRATAP MOULI V, Munot K, Ananthakrishnan A, Kedia S, et al
    Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:27-36.
    PubMed     Abstract available


  419. CHRISTENSEN B, Sparrow MP
    Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:178-179.
    PubMed    


    December 2016
  420. ANGELISON L, Almer S, Eriksson A, Karling P, et al
    Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Aliment Pharmacol Ther. 2016 Dec 27. doi: 10.1111/apt.13893.
    PubMed     Abstract available


  421. CARRAT F, Seksik P, Colombel JF, Peyrin-Biroulet L, et al
    The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 19. doi: 10.1111/apt.13897.
    PubMed     Abstract available


  422. WONG DR, Coenen MJ, Derijks LJ, Vermeulen SH, et al
    Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 12. doi: 10.1111/apt.13879.
    PubMed     Abstract available


    November 2016
  423. KONIG J, Siebenhaar A, Hogenauer C, Arkkila P, et al
    Consensus report: faecal microbiota transfer - clinical applications and procedures.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13868.
    PubMed     Abstract available


  424. ARTOM M, Czuber-Dochan W, Sturt J, Murrells T, et al
    The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study.
    Aliment Pharmacol Ther. 2016 Nov 20. doi: 10.1111/apt.13870.
    PubMed     Abstract available


  425. FEAGAN BG, Patel H, Colombel JF, Rubin DT, et al
    Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Aliment Pharmacol Ther. 2016 Nov 17. doi: 10.1111/apt.13852.
    PubMed     Abstract available


  426. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Abstract available


  427. MAO EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13847.
    PubMed     Abstract available


  428. COLOMBEL JF, Jharap B, Sandborn WJ, Feagan B, et al
    Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Aliment Pharmacol Ther. 2016 Nov 7. doi: 10.1111/apt.13838.
    PubMed     Abstract available


    October 2016
  429. KIRCHGESNER J, Lemaitre M, Rudnichi A, Racine A, et al
    Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Aliment Pharmacol Ther. 2016 Oct 26. doi: 10.1111/apt.13835.
    PubMed     Abstract available


  430. SELINGER CP, Carbery I, Warren V, Rehman AF, et al
    The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Oct 25. doi: 10.1111/apt.13831.
    PubMed     Abstract available


  431. STALLMACH A, Langbein C, Atreya R, Bruns T, et al
    Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Aliment Pharmacol Ther. 2016 Oct 7. doi: 10.1111/apt.13813.
    PubMed     Abstract available


    September 2016
  432. D'HAENS G
    Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Sep 21. doi: 10.1111/apt.13803.
    PubMed     Abstract available


    May 2016
  433. BUISSON A, Vazeille E, Minet-Quinard R, Goutte M, et al
    Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43:1069-79.
    PubMed     Abstract available


    April 2016
  434. KIRCHGESNER J, Sokol H
    Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Aliment Pharmacol Ther. 2016;43:838-9.
    PubMed    


  435. TORRES J, Bao X, Goel A, Colombel JF, et al
    The features of mucosa-associated microbiota in primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2016;43:790-801.
    PubMed     Abstract available


    March 2016
  436. TO N, Gracie DJ, Ford AC
    Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:549-61.
    PubMed     Abstract available


  437. VEDAK P, Kroshinsky D, St John J, Xavier RJ, et al
    Genetic basis of TNF-alpha antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.
    Aliment Pharmacol Ther. 2016;43:697-704.
    PubMed     Abstract available


  438. MONTELEONE G, Di Sabatino A, Ardizzone S, Pallone F, et al
    Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:717-24.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: